Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2002

View Archived Issues

SkyePharma and GeneMedix to develop extended-release interferon alfa-2b

Texas Biotechnology presents mid-year update

Xenical improves weight loss and glycemic control in type 2 diabetes patients on metformin

VaxGen and Genentech revise AIDS vaccine candidate agreement

Inhibitors of ubiquitin ligases as potential new anticancer agents

Antisoma's vascular targeting agent well tolerated in phase I trials

Heat-activated drug therapy for prostate cancer enters clinical trials

U.K. introduction for Amgen's novel rheumatoid arthritis therapeutic

Buprenorphine matrix patch for chronic pain relief launched in U.K.

Biochemical profile of SM-13496, an atypical antipsychotic, characterized in vitro and in vivo

Antipsychotic effects demonstrated in patients for dopamine stabilizer OSU-6162

Preclinical profile of Lu-35-138 described at CINP congress

New data on the efficacy and safety of the antidepressant S-20098

FDA approval for Remicade for remission maintenance of Crohn's disease

Gleevec submitted in U.S. and E.U. for first-line use in CML

E.U. approval for Zenapax in pediatric renal transplantation

Schering AG acquires distribution rights for Testogel in Europe

Reolysin enters phase I/II in brain cancer

Adenylyl cyclase inhibitors and their use in congestive heart failure

Novel PPARalpha agonists in Lilly pipeline

New antibacterial carbapenems in early development at Sankyo

GSK claims tachykinin NK2/NK3 antagonists for respiratory disorders

Bombesin receptor antagonists with potential in sexual dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...